检索历史 清除

Gastric cancer is one of the most common malignancies in China. Currently, surgical resection, chemotherapy and radiotherapy are still the main therapeutic methods.The postoperative 5-year survival of patients with gastric cancer is lower than 60%. As a means of adjuvant therapy, immunotherapy has the potential to improve the survival of patients with gastric cancer, because its therapeutic targeting and toxicity profile does not overlap with those of conventional therapies. The effector cells of the immune system (T, B and NK cells), when activated, are able to lyse and destroy tumor cells through specific recognition of tumor-associated antigens. However, most immunotherapy research in gastric cancer is still limited to the preclinical stage due to the weakness of its antigenicity. With the development of tumor immunobiology and genetic engineering, immunotherapy has become the focus of research for the treatment of gastric cancer.

@@ 胃癌是世界范围内重要的致死疾病之一,在全球新发癌症中占第2位.外科手术仍然是胃癌患者首选的治疗方案.尽管近年来外科手术在不断发展,但其总体5年生存率仅为15%～35%.虽然手术结合新辅助治疗和术后辅助治疗可提高少部分Ⅱ、Ⅲ期胃癌患者的生存率,但胃癌患者总体疗效始终不容乐观.